Gelnique 3% patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7198801 ALLERGAN Formulations for transdermal or transmucosal application
Jun, 2022

(1 year, 3 months ago)

Gelnique 3% is owned by Allergan.

Gelnique 3% contains Oxybutynin.

Gelnique 3% has a total of 1 drug patent out of which 1 drug patent has expired.

Expired drug patents of Gelnique 3% are:

  • US7198801

Gelnique 3% was authorised for market use on 07 December, 2011.

Gelnique 3% is available in gel, metered;transdermal dosage forms.

The generics of Gelnique 3% are possible to be released after 25 June, 2022.

Drugs and Companies using OXYBUTYNIN ingredient

Market Authorisation Date: 07 December, 2011

Treatment: NA


More Information on Dosage

GELNIQUE 3% family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic